Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.73 |
| ▸ | CNR1 | P21554 | 3/20 | 0.68 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.45 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL30341793 | 0.92 | CNR2 (0.74) | CNR2CNR1PLCD1F2PRSS1 | |
| SCHEMBL29688513 | 0.92 | CNR2 (0.78) | CNR2CNR1PLCD1F2PRSS1 | |
| SCHEMBL12989865 | 0.92 | CNR2 (0.68) | CNR2CNR1PLCD1F2PRSS1 | |
| Ammonia Solution, Strong SCHEMBL30341799 | 0.91 | CNR2 (0.71) | CNR2CNR1PLCD1TDP1 | |
| SCHEMBL30165784 | 0.90 | CNR2 (0.66) | CNR2CNR1PLCD1F2PRSS1 | |
| SCHEMBL10140249 | 0.90 | CNR2 (0.66) | CNR2CNR1PLCD1F2PRSS1 | |
| SCHEMBL23521224 | 0.89 | CNR2 (0.57) | CNR2CNR1SELPNR5A2NR5A1 | |
| SCHEMBL29910361 | 0.89 | CNR2 (0.57) | CNR2CNR1SELPNR5A2NR5A1 | |
| SCHEMBL30400770 | 0.89 | CNR2 (0.57) | CNR2CNR1SELPNR5A2NR5A1 | |
| SCHEMBL30231847 | 0.88 | CNR2 (0.74) | CNR2CNR1PLCD1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351600-A1 | METHODS OF ACTIVATING T CELLS | ADOC SSF, LLC (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117835992-A | Method for activating T cells | PACT制药公司 | 2024-04-05 | — | — | CN | claimed |
| US-20240100096-A1 | METHODS OF ACTIVATING T CELLS | ADOC SSF, LLC (US) | 2024-03-28 | — | — | US | claimed |
| WO-2022261392-A1 | METHODS OF ACTIVATING T CELLS | PACT PHARMA, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| WO-2025073824-A1 | PHOSPHOLIPID CONJUGATES AND THEIR USES | AARHUS UNIVERSITET (DK) | 2025-04-10 | — | — | WO | disclosed |
| EP-4351600-A1 | METHODS OF ACTIVATING T CELLS | ADOC SSF, LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240100096-A1 | METHODS OF ACTIVATING T CELLS | ADOC SSF, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-4170031-A1 | APTAMERS AND USES THEREOF | Caris Science, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-02-09 | — | — | US | disclosed |
| WO-2022261392-A1 | METHODS OF ACTIVATING T CELLS | PACT PHARMA, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-115087434-A | Microfluidic production of bio-functionalized giant unilamellar vesicles for targeted cargo delivery | 马克斯·普朗克科学促进学会 | 2022-09-20 | — | — | CN | disclosed |
| EP-4054532-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | PCNA, BOD1L1, SARS1 | CNR2 4217/4885CNR1 3597/4885PLCD1 899/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | CNR2 3696/4885CNR1 3075/4885PLCD1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.